A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Sapanisertib (Primary) ; TAK 580 (Primary) ; Alisertib; Cetuximab; Irinotecan; Paclitaxel
- Indications Cancer
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 26 Oct 2017 Results (n=16) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
- 18 Apr 2017 Planned End Date changed from 1 Jul 2018 to 23 Dec 2017.
- 18 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 23 Dec 2017.